GlaxoSmithKline (NYSE:GSK) has received regulatory approval in Germany and the United Kingdom for its vaccine targeting four strains of influenza.
The quadrivalent vaccine provides immunity against two strains each of influenza virus types A and B. These strains are responsible for causing seasonal flu outbreaks. By protecting against the four strains, the vaccine is intended to reduce the overall incidence of influenza.
The new GlaxoSmithKline flu vaccine will be marketed as Influsplit Tetra in Germany and as Fluarix Tetra in the U.K. London-based GSK operates its U.S. headquarters in Research Triangle Park.
